image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.8
1.12 %
$ 7.87 M
Market Cap
-0.01
P/E
1. INTRINSIC VALUE

Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom.[ Read More ]

The intrinsic value of one NUWE stock under the base case scenario is HIDDEN Compared to the current market price of 1.8 USD, Nuwellis, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NUWE

image
FINANCIALS
8.86 M REVENUE
3.76%
-17.6 M OPERATING INCOME
-2.67%
-20.2 M NET INCOME
-39.13%
-17.9 M OPERATING CASH FLOW
-18.40%
330 K INVESTING CASH FLOW
-97.76%
3.68 M FINANCING CASH FLOW
-60.91%
2.37 M REVENUE
7.89%
-1.53 M OPERATING INCOME
33.97%
2.36 M NET INCOME
130.52%
-2.47 M OPERATING CASH FLOW
10.28%
16 K INVESTING CASH FLOW
166.67%
3.34 M FINANCING CASH FLOW
39.12%
Balance Sheet Decomposition Nuwellis, Inc.
image
Current Assets 8.21 M
Cash & Short-Term Investments 3.8 M
Receivables 1.95 M
Other Current Assets 2.46 M
Non-Current Assets 1.56 M
Long-Term Investments 0
PP&E 1.44 M
Other Non-Current Assets 120 K
Current Liabilities 3.17 M
Accounts Payable 2.38 M
Short-Term Debt 432 K
Other Current Liabilities 360 K
Non-Current Liabilities 3.39 M
Long-Term Debt 544 K
Other Non-Current Liabilities 2.84 M
EFFICIENCY
Earnings Waterfall Nuwellis, Inc.
image
Revenue 8.86 M
Cost Of Revenue 3.88 M
Gross Profit 4.98 M
Operating Expenses 22.6 M
Operating Income -17.6 M
Other Expenses 2.58 M
Net Income -20.2 M
RATIOS
56.22% GROSS MARGIN
56.22%
-198.89% OPERATING MARGIN
-198.89%
-227.99% NET MARGIN
-227.99%
-629.37% ROE
-629.37%
-206.85% ROA
-206.85%
-514.65% ROIC
-514.65%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Nuwellis, Inc.
image
Net Income -20.2 M
Depreciation & Amortization 362 K
Capital Expenditures -248 K
Stock-Based Compensation 670 K
Change in Working Capital -1.42 M
Others 2.59 M
Free Cash Flow -18.2 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Nuwellis, Inc.
image
NUWE has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Nuwellis, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Mar 15, 2023
Bought 19.6 K USD
Jaramillo Nestor Jr.
President and CEO
+ 4098
4.79 USD
5 years ago
Mar 12, 2019
Bought 50 K USD
ERB JOHN L
CEO and President
+ 9523
5.25 USD
5 years ago
Mar 12, 2019
Bought 50 K USD
ERB JOHN L
CEO and President
+ 9523
5.25 USD
5 years ago
Mar 12, 2019
Bought 50 K USD
ERB JOHN L
CEO and President
+ 9523
5.25 USD
6 years ago
Aug 10, 2018
Sell 74.4 USD
WALLER GREGORY D
Director
- 72
1.0338 USD
6 years ago
Jul 03, 2018
Bought 50 K USD
ERB JOHN L
+ 23584
2.12 USD
6 years ago
Nov 22, 2017
Bought 450 USD
ERB JOHN L
CEO and President
+ 100
4.5 USD
6 years ago
Nov 22, 2017
Bought 450 USD
ERB JOHN L
CEO and President
+ 100
4.5 USD
6 years ago
Nov 22, 2017
Bought 450 USD
ERB JOHN L
CEO and President
+ 100
4.5 USD
7 years ago
Oct 12, 2017
Bought 14.5 K USD
Choi Ki Yong
10 percent owner
+ 30141
0.48 USD
7 years ago
Oct 11, 2017
Bought 17.6 K USD
Choi Ki Yong
10 percent owner
+ 31504
0.56 USD
7 years ago
Sep 13, 2017
Bought 50.1 K USD
Choi Ki Yong
10 percent owner
+ 78211
0.64 USD
7 years ago
Aug 10, 2017
Bought 8.48 K USD
Choi Ki Yong
10 percent owner
+ 13253
0.64 USD
7 years ago
Aug 08, 2017
Bought 140 K USD
Choi Ki Yong
10 percent owner
+ 180000
0.78 USD
7 years ago
Apr 19, 2017
Bought 100 K USD
ERB JOHN L
CEO and President
+ 100000
1 USD
7 years ago
Apr 19, 2017
Bought 110 K USD
ERB JOHN L
CEO and President
+ 100000
1.1 USD
7 years ago
Nov 28, 2016
Bought 17.6 K USD
ERB JOHN L
CEO & President
+ 80000
0.2196 USD
8 years ago
Mar 16, 2016
Bought 2.28 K USD
ERB JOHN L
CEO and President
+ 2500
0.91 USD
8 years ago
Mar 15, 2016
Bought 7.6 K USD
ERB JOHN L
CEO and President
+ 8000
0.95 USD
8 years ago
Mar 14, 2016
Bought 6.88 K USD
ERB JOHN L
CEO and President
+ 8000
0.8604 USD
9 years ago
Aug 11, 2015
Bought 25.5 K USD
BUCKMAN PAUL
Director
+ 10000
2.55 USD
10 years ago
Mar 17, 2014
Bought 12.4 K USD
MATHIESEN JEFFREY S
Chief Financial Officer
+ 2000
6.1799 USD
7. News
Nuwellis, Inc. (NUWE) Q3 2024 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q3 2024 Earnings Call Transcript November 11, 2024 9:00 AM ET Company Participants Vivian Cervantes - IR Nestor Jaramillo - President and CEO John Jefferies - CMO Rob Scott - CFO Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good day, everyone, and Welcome to Nuwellis' Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 5 days ago
Nuwellis, Inc. (NUWE) Q3 Earnings Surpass Estimates Nuwellis, Inc. (NUWE) came out with quarterly earnings of $1.74 per share, beating the Zacks Consensus Estimate of a loss of $0.88 per share. This compares to loss of $63.29 per share a year ago. zacks.com - 5 days ago
Nuwellis, Inc. Announces Third Quarter 2024 Financial Results and Recent Highlights MINNEAPOLIS, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the third quarter ended September 30, 2024. globenewswire.com - 5 days ago
Nuwellis Announces Exercise of Warrants for $5.1 Million of Gross Proceeds MINNEAPOLIS, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants issued by the Company on April 30, 2024 (collectively, the “Existing Warrants”) to purchase up to an aggregate of 1,832,517 shares of the Company's common stock at their current exercise price of $2.10 per share for total gross proceeds of approximately $3.8 million, prior to deducting inducement agent fees and estimated offering expenses. An additional $1.3 million of gross proceeds was received through the exercise of warrants over the last week in accordance with their original terms. globenewswire.com - 1 week ago
Nuwellis Receives Increased Reimbursement Rate for Aquadex SmartFlow® Therapy from the Centers for Medicare and Medicaid Reimbursement rate to increase 397% per day effective January 1, 2025 New rate expected to encourage adoption of ultrafiltration therapy in the outpatient setting MINNEAPOLIS, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical device company committed to transforming the lives of people with fluid overload, is pleased to announce that the Centers for Medicare and Medicaid Services (CMS) will reassign the Aquadex ultrafiltration code to the outpatient reimbursement level most consistent with administration of ultrafiltration therapy and cost of treatment. Effective January 1, 2025, the payment rate will increase 397% from $413 to $1,639 per day. globenewswire.com - 1 week ago
Nuwellis Announces Preliminary Results for Third Quarter of 2024 MINNEAPOLIS, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical device company dedicated to transforming the lives of patients suffering from fluid overload, today announced certain preliminary, unaudited results for the quarter ended September 30, 2024. The company plans to report its complete results and host its earnings conference call for the third quarter of 2024 on November 11, 2024. globenewswire.com - 2 weeks ago
Nuwellis Welcomes University of Iowa Health Care Stead Family Children's Hospital as Newest Pediatric Customer MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that University of Iowa Health Care Stead Family Children's Hospital in Iowa City, Iowa, has adopted the Aquadex SmartFlow® system to treat pediatric patients suffering from fluid overload due to heart and kidney disease. globenewswire.com - 2 weeks ago
Nuwellis, Inc. To Report Third Quarter 2024 Financial Results on November 11, 2024 MINNEAPOLIS, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the third quarter of 2024 on Monday, November 11, 2024. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. globenewswire.com - 3 weeks ago
Nuwellis to Present at the Third Annual ROTH Healthcare Opportunities Conference MINNEAPOLIS, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients with fluid overload, is pleased to announce that President and Chief Executive Officer Nestor Jaramillo will participate in ROTH Capital Partners' third annual ROTH Healthcare Opportunities Conference on Wednesday, October 9, 2024. globenewswire.com - 1 month ago
Nuwellis Announces Pricing of $916,000 Registered Direct Offering Priced At-The-Market Under Nasdaq Rules MINNEAPOLIS, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a medical technology company focused on transforming the lives of people with fluid overload, today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of 496,901 shares of the Company's common stock at a price of $1.8450 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. globenewswire.com - 2 months ago
Nuwellis, Inc. (NUWE) Q2 2024 Earnings Call Transcript Nuwellis, Inc. (NASDAQ:NUWE ) Q2 2024 Earnings Conference Call August 13, 2024 9:00 AM ET Company Participants Vivian Cervantes - Gilmartin Group, Investor Relations Nestor Jaramillo - President, CEO & Director Rob Scott - Chief Financial Officer Conference Call Participants Jonathan Aschoff - Roth Anthony Vendetti - Maxim Group Operator Good morning. And welcome to the Nuwellis Earnings Conference Call for the Second Quarter ended June 30th, 2024. seekingalpha.com - 3 months ago
Nuwellis, Inc. Announces Second Quarter 2024 Financial Results MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today reported financial results for the second quarter ended June 30, 2024. globenewswire.com - 3 months ago
8. Profile Summary

Nuwellis, Inc. NUWE

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 7.87 M
Dividend Yield 0.00%
Description Nuwellis, Inc., a medical device company, focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. The company's products are the Aquadex FlexFlow and Aquadex SmartFlow systems, which are indicated for the treatment of patients suffering from fluid overload who have failed diuretics. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States; and through independent specialty distributors primarily in Austria, Brazil, Czech Republic, Germany, Greece, Hong Kong, India, Israel, Italy, Romania, Singapore, Slovakia, Spain, Switzerland, Thailand, the United Arab Emirates, and the United Kingdom. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Contact 12988 Valley View Road, Eden Prairie, MN, 55344 https://www.nuwellis.com
IPO Date Feb. 16, 2012
Employees 59
Officers Mr. Neil P. Ayotte Esq. Senior Vice President, General Counsel, Secretary & Chief Compliance Officer Dr. John Lynn Jefferies FACC, M.B.A., M.D., M.P.H. Chief Medical Officer & Member of Medical Advisory Board Mr. Paul Wotta Corporate Controller Ms. Sandra Eayrs Chief Human Resources Officer Mr. Nestor Jaramillo Jr. President, Chief Executive Officer & Director Mr. Robert B. Scott Chief Financial Officer Mr. John Kowalczyk Senior Vice President of Sales & Marketing